KR20230026449A - (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형 - Google Patents

(1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형 Download PDF

Info

Publication number
KR20230026449A
KR20230026449A KR1020237001959A KR20237001959A KR20230026449A KR 20230026449 A KR20230026449 A KR 20230026449A KR 1020237001959 A KR1020237001959 A KR 1020237001959A KR 20237001959 A KR20237001959 A KR 20237001959A KR 20230026449 A KR20230026449 A KR 20230026449A
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical formulation
formulation
weight
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237001959A
Other languages
English (en)
Korean (ko)
Inventor
로버트 버만
라제쉬 쿠마르
찰스 엠. 콘웨이
메리 케이. 도노휴
아자야 쿠마르 레카
Original Assignee
바이오하벤 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 테라퓨틱스 리미티드 filed Critical 바이오하벤 테라퓨틱스 리미티드
Publication of KR20230026449A publication Critical patent/KR20230026449A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
KR1020237001959A 2020-06-23 2021-06-23 (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형 Withdrawn KR20230026449A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043075P 2020-06-23 2020-06-23
US63/043,075 2020-06-23
PCT/US2021/038564 WO2021262779A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Publications (1)

Publication Number Publication Date
KR20230026449A true KR20230026449A (ko) 2023-02-24

Family

ID=79281832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001959A Withdrawn KR20230026449A (ko) 2020-06-23 2021-06-23 (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형

Country Status (12)

Country Link
US (1) US12564579B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168116A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023531918A (cg-RX-API-DMAC7.html)
KR (1) KR20230026449A (cg-RX-API-DMAC7.html)
CN (1) CN115836052A (cg-RX-API-DMAC7.html)
AU (1) AU2021297823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025900A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187140A1 (cg-RX-API-DMAC7.html)
IL (1) IL299308A (cg-RX-API-DMAC7.html)
MX (1) MX2022016183A (cg-RX-API-DMAC7.html)
PH (1) PH12022553502A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021262779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220093A2 (en) * 2023-04-20 2024-10-24 LifeActive, Inc. Transdermal delivery formulations and methods for the manufacture thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594729A1 (en) * 1991-07-17 1994-05-04 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
DE69317411T2 (de) 1992-04-03 1998-07-30 Ab Astra, Soedertaelje Enantiomere 1-phenyl-2-(2-pyridinyl)ethylamin für die behandlung neurodegenerativer störungen
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases

Also Published As

Publication number Publication date
IL299308A (en) 2023-02-01
WO2021262779A1 (en) 2021-12-30
EP4168116A4 (en) 2024-07-10
AU2021297823A1 (en) 2023-02-16
US20230190719A1 (en) 2023-06-22
EP4168116A1 (en) 2023-04-26
CA3187140A1 (en) 2021-12-30
US12564579B2 (en) 2026-03-03
JP2023531918A (ja) 2023-07-26
MX2022016183A (es) 2023-02-13
PH12022553502A1 (en) 2024-04-22
BR112022025900A2 (pt) 2023-01-10
CN115836052A (zh) 2023-03-21

Similar Documents

Publication Publication Date Title
US6455066B1 (en) Intradermal-penetration agents for topical local anesthetic administration
US10758502B2 (en) High concentration local anesthetic formulations
US9415108B2 (en) Compositions for transdermal delivery of active agents
AU2001245449A1 (en) Intradermal-penetration agents for topical local anesthetic administration
EP3275466A1 (en) Diclofenac formulations
US20130209585A1 (en) Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
WO2008021847A2 (en) Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent
US12564579B2 (en) Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine
US20060276550A1 (en) Topical compositions of ketamine and butamben and methods of their use
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
KR20080041695A (ko) Ｏ-데스메틸 벤라팍신 (ｏｄｖ) 또는 이의 염을 함유하는국소 제형
KR20070059079A (ko) 경피 페로스피론 투여용 의약적 조성물
JP2020100575A (ja) 皮膚外用組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000